BDTX-1535
DescriptionBDTX-1535 is an orally bioavailable, brain-penetrating, mutation-selective, EGFR inhibitor with potential antitumor activity.BDTX-1535 is a fourth-generation EGFR inhibitor that overcomes resistance to Osimertinib, the standard of care for EGFR-mutant non–small...
$190.00